The amphiregulin–epidermal growth factor receptor axis drives fibroblast activation to promote keloid progression
British Journal of Dermatology · 2026
DOI: 10.1093/bjd/ljag289 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Enzhu Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China. Hauptthemen laut MEDLINE: Amphiregulin, Keloid, ErbB Receptors, Fibroblasts. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Keloids represent a prevalent form of pathological scarring, yet their treatment remains highly challenging in clinical practice. The pathogenesis of keloids remains incompletely understood.
Objectives
To investigate the function and mechanism of amphiregulin (AREG) in keloids.
Methods
We performed transcriptomic profiling of keloid fibroblasts (KFs) and normal fibroblasts (NFs). Keloid skin explants and keloid-bearing nude mice were used to explore the roles of AREG in keloids.
Results
AREG was upregulated in keloids and associated with disease severity. In vitro recombinant AREG promoted proliferation, migration and extracellular matrix (ECM) production in KFs. We further demonstrated that AREG signalling mediates keloid fibroblast activation through the epidermal growth factor receptor (EGFR). In addition, we revealed that the MAPK signalling pathway functions as a key downstream effector of the AREG-EGFR axis. As an EGFR antagonist, gefitinib effectively reduced ECM component deposition in both keloid skin explants and a nude mouse xenograft model.
Conclusions
These results not only highlight the role of AREG in driving keloid progression but also point to the translational relevance of gefitinib as a viable therapeutic candidate for keloids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
- Hubei Engineering Research Centre for Skin Repair and Theranostics, Wuhan, China.
- Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
ORCID-Profile: Juan Tao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dong, E., Li, J., Rao, Z., Suo, H., Wu, N., Yan, S., Peng, L., Xu, Y., Zhang, Y., Yang, Z., Tao, J., & Yang, L. (2026). The amphiregulin–epidermal growth factor receptor axis drives fibroblast activation to promote keloid progression. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag289
Vancouver
Dong E, Li J, Rao Z, Suo H, Wu N, Yan S, et al. The amphiregulin–epidermal growth factor receptor axis drives fibroblast activation to promote keloid progression. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag289
BibTeX
@article{Dong2026,
author = {Dong, Enzhu and Li, Jun and Rao, Zhenqi and Suo, Huinan and Wu, Naming and Yan, Shiyi and Peng, Lianqi and Xu, Yuke and Zhang, Yuan and Yang, Zican and Tao, Juan and Yang, Liu},
title = {The amphiregulin–epidermal growth factor receptor axis drives fibroblast activation to promote keloid progression},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljag289}
}
EUVIMED